On Jun. 29, 2021, Paratek Pharmaceuticals announced it has delivered the first procurement of NUZYRA to the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), and BARDA has taken title of the product. This procurement is valued at ~$38 million and will be recognized in the Company’s second quarter 2021 net sales of NUZYRA.

In December 2019, BARDA awarded Paratek a five-year contract, valued at up to $284.5 million, to support: 1) the development of NUZYRA for the treatment of pulmonary anthrax; 2) U.S. Food and Drug Administration post-marketing requirements associated with the initial NUZYRA approval; 3) U.S. onshoring of NUZYRA and manufacturing security requirements, and 4) up to four procurements of NUZYRA. As described above, BARDA has taken title of the first procurement under the contract.

Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.